Cargando…

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma

BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, LJ, Thielen, FW, Redekop, WK, Groot, CA Uyl-de, Blommestein, HM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226243/
https://www.ncbi.nlm.nih.gov/pubmed/37248477
http://dx.doi.org/10.1186/s12874-023-01952-2
_version_ 1785050536865693696
author Bakker, LJ
Thielen, FW
Redekop, WK
Groot, CA Uyl-de
Blommestein, HM
author_facet Bakker, LJ
Thielen, FW
Redekop, WK
Groot, CA Uyl-de
Blommestein, HM
author_sort Bakker, LJ
collection PubMed
description BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and the assumptions made about the survival hazard. Here, we analyze the accuracy of different extrapolation techniques while varying the data cut-off to estimate long-term survival in newly diagnosed multiple myeloma (MM) patients. METHODS: Empirical data were available from a randomized controlled trial and a registry for MM patients treated with melphalan + prednisone, thalidomide, and bortezomib- based regimens. Standard parametric and spline models were fitted while artificially reducing follow-up by introducing database locks. The maximum follow-up for these locks varied from 3 to 13 years. Extrapolated (conditional) restricted mean survival time (RMST) was compared to the Kaplan-Meier RMST and models were selected according to statistical tests, and visual fit. RESULTS: For all treatments, the RMST error decreased when follow-up and the absolute number of events increased, and censoring decreased. The decline in RMST error was highest when maximum follow-up exceeded six years. However, even when censoring is low there can still be considerable deviations in the extrapolated RMST conditional on survival until extrapolation when compared to the KM-estimate. CONCLUSIONS: We demonstrate that both standard parametric and spline models could be worthy candidates when extrapolating survival for the populations examined. Nevertheless, researchers and decision makers should be wary of uncertainty in results even when censoring has decreased, and the number of events has increased. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01952-2.
format Online
Article
Text
id pubmed-10226243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102262432023-05-30 Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma Bakker, LJ Thielen, FW Redekop, WK Groot, CA Uyl-de Blommestein, HM BMC Med Res Methodol Research BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and the assumptions made about the survival hazard. Here, we analyze the accuracy of different extrapolation techniques while varying the data cut-off to estimate long-term survival in newly diagnosed multiple myeloma (MM) patients. METHODS: Empirical data were available from a randomized controlled trial and a registry for MM patients treated with melphalan + prednisone, thalidomide, and bortezomib- based regimens. Standard parametric and spline models were fitted while artificially reducing follow-up by introducing database locks. The maximum follow-up for these locks varied from 3 to 13 years. Extrapolated (conditional) restricted mean survival time (RMST) was compared to the Kaplan-Meier RMST and models were selected according to statistical tests, and visual fit. RESULTS: For all treatments, the RMST error decreased when follow-up and the absolute number of events increased, and censoring decreased. The decline in RMST error was highest when maximum follow-up exceeded six years. However, even when censoring is low there can still be considerable deviations in the extrapolated RMST conditional on survival until extrapolation when compared to the KM-estimate. CONCLUSIONS: We demonstrate that both standard parametric and spline models could be worthy candidates when extrapolating survival for the populations examined. Nevertheless, researchers and decision makers should be wary of uncertainty in results even when censoring has decreased, and the number of events has increased. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01952-2. BioMed Central 2023-05-29 /pmc/articles/PMC10226243/ /pubmed/37248477 http://dx.doi.org/10.1186/s12874-023-01952-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bakker, LJ
Thielen, FW
Redekop, WK
Groot, CA Uyl-de
Blommestein, HM
Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title_full Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title_fullStr Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title_full_unstemmed Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title_short Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
title_sort extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226243/
https://www.ncbi.nlm.nih.gov/pubmed/37248477
http://dx.doi.org/10.1186/s12874-023-01952-2
work_keys_str_mv AT bakkerlj extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma
AT thielenfw extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma
AT redekopwk extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma
AT grootcauylde extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma
AT blommesteinhm extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma